Internal Medicine, Endocrinology, Diabetes, & Metabolism · Trumbull, CT
NPI
1205034600
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
112 Quarry Rd, Suite 250
Trumbull, CT, 06611
Phone (203) 372-7200
Groups this clinician bills Medicare through
Medicare paid, 2024
$298K
15,706 services
Medicare patients, 2024
365
Average age 75
Drug cost, 2024
$5.1M
8,103 prescriptions
Company payments, 2025
$371
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Judith M Castillo was code J0897 (injection, denosumab, 1 mg), 8,040 times for 80 patients. In total Judith M Castillo billed 15,706 services in 22 codes, and Medicare paid $298K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-01-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 8,040 | 80 | $20.45 | $164K |
| 99214 Office E&M - Established | Office | 523 | 287 | $99.83 | $52K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 248 | 192 | $13.95 | $3,459 |
| 82962 Clinical Chemistry | Office | 232 | 120 | $3.21 | $745 |
| 96372 Injection Administration | Office | 184 | 88 | $11.36 | $2,090 |
| 99213 Office E&M - Established | Office | 112 | 102 | $68.68 | $7,692 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 70 | 14 | $3.51 | $246 |
| 83036 Blood Count | Office | 70 | 53 | $9.52 | $666 |
| 95251 Test - Miscellaneous | Office | 48 | 30 | $28.51 | $1,368 |
| 76536 Ultrasound - Nonspecific | Office | 38 | 37 | $84.71 | $3,219 |
| 96365 Intravenous Infusion, Hydration | Office | 14 | 14 | $39.57 | $554 |
By year: 2022 $227K for 10,445 services; 2023 $267K for 14,069 services; 2024 $298K for 15,706 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 232 | 120 | $3.21 | $745 |
| 83036 Blood Count | 70 | 53 | $9.52 | $666 |
Medicare prescription drug claims, 2024
In 2024, the drug Judith M Castillo prescribed most often to Medicare patients was Levothyroxine Sodium, with 709 prescriptions and refills. In total Judith M Castillo wrote 8,103 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 709 | 1,962 | 214 | $7,847 |
| Mounjaro Tirzepatide | 630 | 842 | 103 | $901K |
| Ozempic Semaglutide | 517 | 875 | 121 | $841K |
| Jardiance Empagliflozin | 509 | 1,163 | 130 | $680K |
| Synthroid Levothyroxine Sodium | 492 | 1,396 | 145 | $59K |
| Rosuvastatin Calcium Generic | 308 | 823 | 92 | $3,237 |
| Atorvastatin Calcium Generic | 237 | 632 | 76 | $1,776 |
| Metformin Hcl Er Metformin Hcl | 224 | 616 | 67 | $1,600 |
| Synjardy Xr Empagliflozin/Metformin Hcl | 203 | 411 | 46 | $241K |
| Tresiba Flextouch U-200 Insulin Degludec | 193 | 434 | 58 | $170K |
| Metformin Hcl Generic | 182 | 472 | 56 | $994 |
| Pioglitazone Hcl Generic | 160 | 404 | 44 | $1,207 |
| Unithroid Levothyroxine Sodium | 147 | 372 | 42 | $5,346 |
| Glimepiride Generic | 141 | 369 | 42 | $902 |
| Trulicity Dulaglutide | 123 | 232 | 39 | $224K |
Brand drugs: 4,528 claims; generic drugs: 3,043 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Judith M Castillo $371 ($371 in general payments such as food, travel and fees) from 1 company. The largest payer was Abbott Laboratories with $371.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 20 | $371 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.